3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
40
Recurrence
3
Smoldering Multiple Myeloma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Immunoglobulin Light-chain Amyloidosis
2
Renal Insufficiency
1
Purpura
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Macroglossia
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hepatomegaly
1
Hematologic Neoplasms
1
Gastrointestinal Hemorrhage
1
Diarrhea
1
Constipation
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
isatuximab
×
1 year
×
Clear all
NCT05690984
2026-03-16
EMAT
Medical College of Wisconsin
Phase 2
Active not recruiting
30 enrolled